Who are the key players in North America Molecular Infectious Disease Testing Market industry?

The top five players in the North America Molecular Infectious Disease Testing Market include Roche Diagnostics, Abbott Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, and Hologic Inc. These companies offer advanced molecular diagnostics platforms and are focused on innovation, strategic partnerships, and expanding their infectious disease testing portfolios across North America.

Which segment accounted for the largest North America Molecular Infectious Disease Testing Market share?

The respiratory diseases segment, including testing for influenza, RSV, and COVID-19, accounted for the largest market share. Heightened demand during the COVID-19 pandemic and persistent influenza outbreaks have fueled robust growth in this segment, as leading companies launch multiplex assays for rapid pathogen identification.

What are the factors driving the North America Molecular Infectious Disease Testing Market?

Key drivers include increased prevalence of infectious diseases, technological advancements in PCR and NGS (next-generation sequencing), and supportive regulatory frameworks. For example, Abbott Laboratories has introduced ultra-sensitive molecular kits, enabling faster and more accurate detection and boosting market growth.

Which type accounted for the largest North America Molecular Infectious Disease Testing Market share?

PCR (Polymerase Chain Reaction) based tests represented the largest share of the North American market. These tests are favored due to their high sensitivity, specificity, and ability to deliver rapid results. Major diagnostics companies are consistently innovating within this type to enhance efficiency and broaden detection capabilities.

Home Healthcare

North America Molecular Infectious Disease Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Molecular Infectious Disease Testing Market
Brand: Bussiness Insights

North America Molecular Infectious Disease Testing Market: by Type (PCR, Isothermal Nucleic Acid Amplification, DNA Microarray, Hybridization, Next-Generation Sequencing, Others), Application (Respiratory Diseases, Hepatitis, HIV, Gastrointestinal Diseases, Hospital-Acquired Infections, Others), Distribution Channels (Hospitals, Diagnostic Laboratories, Research Institutes, Point-of-Care Testing, Retail Pharmacies, Others), Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification, DNA Microarray, Hybridization, Next-Generation Sequencing, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20315 | Author: Mike

RD TOC Segmentation Research Methodology Request For Free Sample

North America Molecular Infectious Disease Testing Market Outlook (2025-2035)

The North America Molecular Infectious Disease Testing Market is characterized by rapid advancements in molecular diagnostics, offering precise, timely identification of pathogens. Leveraging technologies such as PCR, isothermal nucleic acid amplification, and next-generation sequencing, the market enables effective detection and management of various infectious diseases including respiratory illnesses, hepatitis, HIV, and hospital-acquired infections. This market comprises a broad spectrum of applications spanning hospitals, diagnostic laboratories, research institutes, point-of-care testing, and retail pharmacies. The sector is witnessing substantial investment, fierce competition, and technological innovation, which drive accessibility and accuracy across the region, particularly in the US, Canada, and Mexico.

North America Molecular Infectious Disease Testing Market Outlook (2025-2035) – Key Market Insights
Key Market Question	Answer

Rising incidence of infectious diseases and hospital-acquired infections, fueling demand for rapid diagnostics. For example, Abbott Laboratories expanded its Alinity m molecular testing platform in 2024 to cover more infectious agents.
Advancements in molecular testing technologies, particularly automation and multiplex PCR systems, leading to enhanced throughput and accuracy. Roche Diagnostics launched its new Cobas Pro integrated platform in June 2024 to streamline workflow in laboratories.

Integration of point-of-care molecular testing for quick disease identification outside traditional labs. In 2024, Cepheid (Danaher Corporation) released expanded testing panels for respiratory viruses at the point-of-care.
Adoption of next-generation sequencing for high-throughput infectious disease research and surveillance, as seen with Thermo Fisher Scientific launching new NGS panels in early 2024 for comprehensive pathogen detection.

Expanding test menu for respiratory and multi-pathogen panels, especially relevant after the COVID-19 pandemic. Hologic Inc. launched its Panther Fusion module for broad respiratory panel testing in 2024.
Growing partnerships between diagnostic vendors and healthcare providers to improve test access and adoption. In 2024, Siemens Healthineers collaborated with major US hospital networks to deploy molecular testing platforms.

Complex regulatory requirements, particularly for novel molecular assays, may delay market entry. Companies like Qiagen faced regulatory review extensions for new NAAT products in Q3 2024.
High cost of advanced molecular testing platforms and reagents, challenging adoption in mid-sized and smaller labs. Bio-Rad Laboratories reported market uptake constraints among medium-sized US labs in its Q2 2024 financial update.

In 2025, Polymerase Chain Reaction (PCR) dominates the North America Molecular Infectious Disease Testing Market, capturing the largest market share at 47%. PCR's prominence is attributed to its accuracy, broad application range, and ongoing technological refinement. Isothermal Nucleic Acid Amplification follows with 21%, benefiting from its rapid turnaround and ease of use in point-of-care settings. Next-Generation Sequencing accounts for 15%, reflecting its rising role for detailed pathogen analysis and outbreak surveillance. DNA Microarray, Hybridization, and Others collectively make up the remaining 17%. The dominance of PCR and rapid amplification technologies showcase the region's preference for quick, reliable diagnostics as the demand for advanced molecular tools escalates.

In 2025, Respiratory Diseases represent the largest application segment in the North America market, accounting for 38% of total demand. The continued burden of respiratory pathogens post-pandemic drives sustained demand for molecular assays in this area. Hospital-Acquired Infections garner 22%, reflecting hospitals’ emphasis on infection surveillance and prevention. HIV and Hepatitis testing together constitute 25% (HIV at 14% and Hepatitis at 11%) as molecular assays remain essential tools for management and monitoring of these chronic infections. Gastrointestinal Diseases capture 9%, with Others comprising the remaining 6%. Overall, the dominance of respiratory and hospital infection applications underlines the market’s focus on early detection and public health response.

The North America Molecular Infectious Disease Testing Market is projected to grow from 5630 million USD in 2020 to 10450 million USD by 2035. The years 2020-2025 witness sharp growth due to increased demand for respiratory and multi-pathogen testing triggered by the COVID-19 pandemic. Post-2025, the market stabilizes yet maintains a robust upward trajectory, propelled by technological innovations, expansion in testing menus, and growing adoption across diverse healthcare settings. Ongoing investments in automation and next-generation technologies further fuel revenue expansion through the forecast period.

Year-on-year (YOY) growth for the North America Molecular Infectious Disease Testing Market peaked at 11.8% from 2020 to 2021 due to pandemic-driven demand. Growth then moderates to 6.2% between 2025 and 2030, and further to 4.5% from 2030 to 2035. This reflects the normalization post-pandemic, a maturing diagnostics market, and strengthened adoption of routine molecular screening protocols in clinical settings. Steady YOY increases signal sustained sector investment and expanding diagnostic access across the region.

The United States dominates the North America Molecular Infectious Disease Testing Market in 2025 with a commanding 79% share, attributed to advanced healthcare infrastructure, higher testing volumes, and a strong presence of key market players. Canada follows with a 13% share, reflecting growing investment in diagnostic technologies and national health system initiatives. Mexico holds 8%, stimulated by improved healthcare system funding and expanding laboratory capabilities. The regional distribution underscores the US as the principal innovator and adopter, with Canada and Mexico contributing steadily rising demand.

Roche Diagnostics leads with 23% share in the North America Molecular Infectious Disease Testing Market, owing to its robust molecular diagnostics portfolio. Abbott Laboratories holds the second largest share at 17% due to widespread adoption of its Alinity and m2000 platforms, followed by Hologic Inc. at 14%, benefiting from its Panther Fusion system. Becton, Dickinson and Company, Thermo Fisher Scientific, Cepheid (Danaher), and others jointly make up the remaining 46%. This distribution reflects a highly competitive landscape dominated by established multinational players supporting broad market penetration.

Hospitals form the largest buyer segment in 2025, securing 52% of the North America molecular infectious disease testing market due to high-volume routine and emergency molecular testing. Diagnostic Laboratories hold a 28% share, driven by specialized and reference testing services. Point-of-Care Testing accounts for 12% as decentralized testing gains traction, while Research Institutes and Other buyers (including retail pharmacies) represent the remaining 8%. The distribution highlights the central role of hospitals and labs, with growing opportunities in decentralized and community-based care.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	7640
Regions	United States, Canada, Mexico
Segments	Type: PCR, Isothermal Nucleic Acid Amplification, DNA Microarray, Hybridization, Next-Generation Sequencing, Others; Application: Respiratory Diseases, Hepatitis, HIV, Gastrointestinal Diseases, Hospital-Acquired Infections, Others; Distribution Channels: Hospitals, Diagnostic Laboratories, Research Institutes, Point-of-Care Testing, Retail Pharmacies, Others; Technology: PCR, Isothermal Nucleic Acid Amplification, DNA Microarray, Hybridization, Next-Generation Sequencing, Others; Organization Size: Small, Medium, Large
Players	Roche Diagnostics, Abbott Laboratories, Hologic Inc., bioMérieux, Thermo Fisher Scientific, Siemens Healthineers, Becton Dickinson and Company, Cepheid (Danaher Corporation), Qiagen, Bio-Rad Laboratories, GenMark Diagnostics, Luminex Corporation, Grifols, Diasorin, Others

June 2024: Roche Diagnostics launched its Cobas Pro integrated platform in North America, enhancing laboratory workflow and throughput for molecular testing.
July 2024: Cepheid (Danaher Corporation) received FDA clearance for expanded respiratory virus panel including SARS-CoV-2 and RSV.
August 2024: Thermo Fisher Scientific introduced new NGS panels targeted for rapid, high-throughput infectious disease surveillance across hospital networks.
September 2024: Siemens Healthineers announced strategic collaborations with US hospital systems for deployment of advanced molecular diagnostics solutions.
October 2024: Abbott Laboratories expanded distribution of its Alinity m platform to cover additional infectious disease assays in the United States and Canada.

About the Author

Mike

Lead Industry Analyst

Mike is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Mike brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Mike has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America Molecular Infectious Disease Testing Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Molecular Infectious Disease Testing Market Outlook (2025-2035)

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type, 2025

Market Share by Application, 2025

Market Revenue (USD Million), 2020-2035

Market YOY Growth (%), 2020-2035

Market Share by Region, 2025

Market Players Share, 2025

Market Buyers Share, 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports